Marinus Pharmaceuticals (NASDAQ:MRNS) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research note issued on Thursday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Several other equities research analysts have also commented on the company. TD Cowen restated a “hold” rating on shares of Marinus Pharmaceuticals in a research note on Friday, October 25th. HC Wainwright reiterated a “neutral” rating and issued a $2.00 price target on shares of Marinus Pharmaceuticals in a research note on Thursday, November 14th. Truist Financial lowered Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 24th. Jefferies Financial Group reiterated a “hold” rating and issued a $0.50 price target (down previously from $5.00) on shares of Marinus Pharmaceuticals in a research note on Friday, October 25th. Finally, JMP Securities reiterated a “market perform” rating on shares of Marinus Pharmaceuticals in a research note on Thursday, October 24th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $4.79.

Marinus Pharmaceuticals Price Performance

NASDAQ:MRNS opened at $0.55 on Thursday. The firm has a market capitalization of $30.37 million, a price-to-earnings ratio of -0.22 and a beta of 1.03. Marinus Pharmaceuticals has a one year low of $0.22 and a one year high of $10.50. The business has a fifty day moving average price of $0.42 and a 200-day moving average price of $0.92.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Deltec Asset Management LLC bought a new position in shares of Marinus Pharmaceuticals during the 4th quarter valued at about $107,000. JPMorgan Chase & Co. boosted its holdings in shares of Marinus Pharmaceuticals by 1,968.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 133,191 shares of the biopharmaceutical company’s stock valued at $234,000 after purchasing an additional 126,752 shares during the last quarter. Franklin Resources Inc. boosted its holdings in shares of Marinus Pharmaceuticals by 34.9% during the 3rd quarter. Franklin Resources Inc. now owns 4,713,014 shares of the biopharmaceutical company’s stock valued at $8,483,000 after purchasing an additional 1,219,871 shares during the last quarter. World Investment Advisors LLC bought a new position in shares of Marinus Pharmaceuticals during the 3rd quarter valued at about $104,000. Finally, Jacobs Levy Equity Management Inc. boosted its holdings in shares of Marinus Pharmaceuticals by 39.5% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 414,269 shares of the biopharmaceutical company’s stock valued at $729,000 after purchasing an additional 117,255 shares during the last quarter. Institutional investors own 98.80% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.